AgelessRx vs Kin Meds
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
AgelessRx
Best for longevity-focused GLP-1 care (pending verification)Starting at $199/mo
Kin Meds
Best for patients who want both compounded and brand-name GLP-1 options on one platform with publicly-disclosed pricing, plus a multi-modality longevity stack — willing to verify the actual brand-name dispensing pathway during intake (whether $149 reflects commercial insurance + manufacturer savings card or a different mechanism)Starting at $149/mo
Side-by-Side Comparison
| Feature | AgelessRx | Kin Meds |
|---|---|---|
| Overall Score | 7.1/10 | ✓7.3/10 |
| Starting Price | $199/mo | ✓$149/mo |
| Editorial Rating | 3.6 ★ /5 | ✓3.7 ★ /5 |
| Features | 6 features | ✓12 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | ✓ Yes | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
AgelessRx
Pros
- ✓Established brand based in Ann Arbor, MI with US-licensed providers
- ✓Offers both compounded and brand-name (Wegovy) options
- ✓Longevity-first positioning — patients get a broader metabolic health framing vs single-condition GLP-1 funnels
- ✓Listed in both competitor directories
Cons
- ✗Stub entry — pricing, states served, and GLP-1-specific intake workflow need YMYL verification
- ✗Confidence LOW until verified
- ✗Longevity-first positioning means GLP-1 is one of several products — patients looking specifically for GLP-1 care may be funneled into a broader longevity intake
Kin Meds
Pros
- ✓$199/mo compounded semaglutide and $249/mo compounded tirzepatide are publicly disclosed (uncommon pricing transparency)
- ✓Brand-name medications offered alongside compounded — Wegovy injection + pill, Zepbound, Foundayo all listed at $149/mo entry pricing (likely the manufacturer copay-card price for commercially insured patients)
- ✓LegitScript verification seal displayed
- ✓Verbatim regulatory disclosure clearly identifies Kin Meds as the telehealth/intake platform and the 'licensed third-party pharmacy' as the dispenser — material YMYL transparency
- ✓Multi-modality longevity menu (Sermorelin, NAD+, Glutathione) plus TRT + hair + skin + sexual health for cross-product retention
- ✓Telehealth flow (questionnaire → provider review → tailored plan → ongoing support) clearly disclosed
Cons
- ✗Specific legal entity name + state of incorporation NOT publicly disclosed
- ✗Specific 'licensed third-party pharmacy' partner NOT named (verbatim disclosure acknowledges Kin Meds is NOT itself a state-licensed pharmacy)
- ✗Per-state availability NOT enumerated
- ✗$149/mo brand-name pricing for Wegovy/Zepbound/Foundayo is the entry tier — typical floors are commercial-insurance-with-savings-card; cash-pay patients should expect higher real-world costs (NovoCare $299 sema, LillyDirect $299-$449 tirz)
- ✗First-month promotional pricing NOT disclosed
- ✗Lab work + dose-titration support NOT clearly disclosed in marketing copy
- ✗Multi-product breadth (8+ categories) signals broad DTC telehealth rather than GLP-1-specialist platform
Our Verdict
Kin Meds edges out AgelessRx with a higher overall score of 7.3/10 and is particularly strong for patients who want both compounded and brand-name GLP-1 options on one platform with publicly-disclosed pricing, plus a multi-modality longevity stack — willing to verify the actual brand-name dispensing pathway during intake (whether $149 reflects commercial insurance + manufacturer savings card or a different mechanism). AgelessRx remains a solid alternative, especially if you're looking for longevity-focused GLP-1 care (pending verification).
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.